Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 | Zendy

J.J. Eron | Zendy; C. Orkin | Zendy; D. Cunningham | Zendy; F. Pulido | Zendy; F.A. Post | Zendy; S. De Wit | Zendy; E. Lathouwers | Zendy; V. Hufkens | Zendy; B. Vandercam | Zendy; J. Jezorwski | Zendy; R. Petrovic | Zendy; K. Brown | Zendy; E. Van Landuyt | Zendy; M. Opsomer | Zendy; E. Florence | Zendy; M. Moutschen | Zendy; E. Van Wijngaerden | Zendy; L. Vandekerckhove | Zendy; J. Brunetta | Zendy; B. Conway | Zendy; M. Klein | Zendy; D. Murphy | Zendy; A. Rachlis | Zendy; S. Shafran | Zendy; S. Walmsley | Zendy; F. Ajana | Zendy; L. Cotte | Zendy; P.-M. Girardy | Zendy; Christine Katlama | Zendy; J.-M. Molina | Zendy; I. Poizot-Martin | Zendy; F. Raffi | Zendy; D. Rey | Zendy; J. Reynes | Zendy; E. Teicher | Zendy; Y. Yazdanpanah | Zendy; J. Gasiorowski | Zendy; W. Halota | Zendy; Andrzej Jerzy Horban | Zendy; A. Piekarska | Zendy; A. Witor | Zendy; J.R. Arribas | Zendy; I. Perez-Valero | Zendy; J. Berenguer | Zendy; J. Casado | Zendy; J.M. Gatell | Zendy; F. Gutierrez | Zendy; M.J. Galindo | Zendy; M.D.M. Gutierrez | Zendy; J.A. Iribarren | Zendy; H. Knobel | Zendy; E. Negredo | Zendy; J.A. Pineda | Zendy; D. Podzamczer | Zendy; Joaquin Portilla Sogorb | Zendy; C. Ricart | Zendy; A. Rivero | Zendy; I. Santos Gil | Zendy; A. Blaxhult | Zendy; L. Flamholc | Zendy; Magnus Gisslén | Zendy; A. Thalme | Zendy; J. Fehr | Zendy; A. Rauch | Zendy; M. Stoeckle | Zendy; A. Clarke | Zendy; B.G. Gazzard | Zendy; Melina Johnson | Zendy; F. Post | Zendy; A. Ustianowski | Zendy; Louise Waters | Zendy; J. Bailey | Zendy; Princess Yaa Benson | Zendy; L. Bhatti | Zendy; I. Brar | Zendy; U.F. Bredeek | Zendy; C. Brinson | Zendy; GE Crofoot | Zendy; E. DeJesus | Zendy; C. Dietz | Zendy; R. Dretler | Zendy; J. Eron | Zendy; F. Felizarta | Zendy; C. Fichtenbaum | Zendy; J. Gallant | Zendy; J. Gathe | Zendy; D. Hagins | Zendy; S. Henn | Zendy; W.K. Henry | Zendy; G. Huhn | Zendy; M. Jain | Zendy; C. Lucasti | Zendy; Catalina Puigserver Martorell | Zendy; C. McDonald | Zendy; A. Mills | Zendy; J. Morales-Ramirez | Zendy; K. Mounzer | Zendy; R. Nahass | Zendy; Hannah B Olivet | Zendy; O. Osiyemi | Zendy; DJ Prelutsky | Zendy; M. Ramgopal | Zendy; B. Rashbaum | Zendy; G. Richmond | Zendy; P. Ruane | Zendy; A. Scarsella | Zendy; A. Scribner | Zendy; P. Shalit | Zendy; D. Shamblaw | Zendy; J. Slim | Zendy; K. Tashima | Zendy; GENE VOSKUHL | Zendy; D. Ward | Zendy; A. Wilkin | Zendy; J. de Vente | Zendy; EMERALD study group | Zendy

Open Access

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Author(s) -

J.J. Eron,

C. Orkin,

D. Cunningham,

F. Pulido,

F.A. Post,

S. De Wit,

E. Lathouwers,

V. Hufkens,

B. Vandercam,

J. Jezorwski,

R. Petrovic,

K. Brown,

E. Van Landuyt,

M. Opsomer,

E. Florence,

M. Moutschen,

E. Van Wijngaerden,

L. Vandekerckhove,

J. Brunetta,

B. Conway,

M. Klein,

D. Murphy,

A. Rachlis,

S. Shafran,

S. Walmsley,

F. Ajana,

L. Cotte,

P.-M. Girardy,

Christine Katlama,

J.-M. Molina,

I. Poizot-Martin,

F. Raffi,

D. Rey,

J. Reynes,

E. Teicher,

Y. Yazdanpanah,

J. Gasiorowski,

W. Halota,

Andrzej Jerzy Horban,

A. Piekarska,

A. Witor,

J.R. Arribas,

I. Perez-Valero,

J. Berenguer,

J. Casado,

J.M. Gatell,

F. Gutierrez,

M.J. Galindo,

M.D.M. Gutierrez,

J.A. Iribarren,

H. Knobel,

E. Negredo,

J.A. Pineda,

D. Podzamczer,

Joaquin Portilla Sogorb,

C. Ricart,

A. Rivero,

I. Santos Gil,

A. Blaxhult,

L. Flamholc,

Magnus Gisslén,

A. Thalme,

J. Fehr,

A. Rauch,

M. Stoeckle,

A. Clarke,

B.G. Gazzard,

Melina Johnson,

F. Post,

A. Ustianowski,

Louise Waters,

J. Bailey,

Princess Yaa Benson,

L. Bhatti,

I. Brar,

U.F. Bredeek,

C. Brinson,

GE Crofoot,

E. DeJesus,

C. Dietz,

R. Dretler,

J. Eron,

F. Felizarta,

C. Fichtenbaum,

J. Gallant,

J. Gathe,

D. Hagins,

S. Henn,

W.K. Henry,

G. Huhn,

M. Jain,

C. Lucasti,

Catalina Puigserver Martorell,

C. McDonald,

A. Mills,

J. Morales-Ramirez,

K. Mounzer,

R. Nahass,

Hannah B Olivet,

O. Osiyemi,

DJ Prelutsky,

M. Ramgopal,

B. Rashbaum,

G. Richmond,

P. Ruane,

A. Scarsella,

A. Scribner,

P. Shalit,

D. Shamblaw,

J. Slim,

K. Tashima,

GENE VOSKUHL,

D. Ward,

A. Wilkin,

J. de Vente,

EMERALD study group

Publication year - 2019

Publication title -

carolina digital repository (university of north carolina at chapel hill)

Language(s) - English

DOI - 10.17615/pn34-7p83

Subject(s) - emtricitabine , tenofovir , randomized controlled trial , medicine , emerald , pharmacology , chemistry , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , mineralogy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research